Subscribe To
VALN / Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
Content Topics
Valneva
Present
Chikungunya
Vaccine
Candidate
Host
Roundtable
Congress
Washington
Stock
VALN
VALN News
By GlobeNewsWire
October 11, 2023
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will pre more_horizontal
By GlobeNewsWire
August 31, 2023
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
Saint- Herb lain (France ) , August 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that more_horizontal
By Zacks Investment Research
June 21, 2023
Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?
Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal
By GlobeNewsWire
May 31, 2023
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
Saint- Herb lain (France) , May 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its more_horizontal
By Zacks Investment Research
May 30, 2023
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program. more_horizontal
By Seeking Alpha
May 6, 2023
Valneva SE (VALN) Q1 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chair more_horizontal
By GlobeNewsWire
March 30, 2023
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will prese more_horizontal
By Seeking Alpha
March 29, 2023
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future
Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine c more_horizontal